Research programme: melanocortin receptor agonists - Competitive Technologies/XION
Latest Information Update: 15 Sep 2009
At a glance
- Originator Competitive Technologies - XION Corporation (JV)
- Class Hormones; Peptides
- Mechanism of Action Melanocortin receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Phase Unknown Obesity; Sexual function disorders
Most Recent Events
- 09 Sep 2009 Investigation in Obesity in USA (unspecified route)
- 09 Sep 2009 Investigation in Sexual function disorders in USA (unspecified route)